Searchable abstracts of presentations at key conferences in endocrinology

ea0010p95 | Thyroid | SFE2005

Thyroid dysfunction in HIV

Qureshi A , Panahloo A , Seal L

A 54 yr old man presented with a six-month history of palpitations, sweating and weight loss. He had a past history of hypertension, type II diabetes, asthma and was HIV-1 seropositive since 14 yrs and was taking potent anti-retroviral therapy: Nevirapine 200 mg bd; Kaletra 3 capsules bd; and didanosine ec 400 mg od.Investigations confirmed Graves thyrotoxicosis (fT4 72.1 pmol/l; TSH <0.01 mU/l; and TSH receptor antibody positive). He was initially t...

ea0090p29 | Calcium and Bone | ECE2023

TransCon PTH Improves Health-Related Quality of Life and Reduces Work Limitations in Adults With Hypoparathyroidism: Patient-Reported Outcomes in the Phase 3 PaTHway Trial

Palermo Andrea , Khan Aliya , Rubin Mishaela , Schwarz Peter , Shoback Dolores M. , Gagnon Claudia , Cetani Filomena , Clarke Bart L. , Tsourdi Elena , Kohlmeier Lynn , Sikjaer Tanja , M Kaiser Stephanie , Lai Bryant , Le John , Ukena Jenny , Sibley Christopher , Shu Aimee , An Xubei , Noori Wahidullah , Smith Alden , Vokes Tamara J.

Background: Individuals with hypoparathyroidism often experience a range of symptoms associated with reduced health-related quality of life (HRQoL) and work productivity. Conventional therapy aims to alleviate hypocalcemia and acute symptoms but fails to restore normal parathyroid hormone (PTH) physiology or improve HRQoL. In the PaTHway trial, 79% of participants treated with TransCon PTH vs. 5% placebo (P<0.0001) met the primary efficacy endpoint (normal serum c...

ea0070aep180 | Bone and Calcium | ECE2020

Baseline characteristics from the observational paradighm registry of patients with chronic hypoparathyroidism

L Clarke Bart , Rejnmark Lars , Ing Steven , Luisa Brandi Maria , Björnsdottir Sigridur , Hahner Stefanie , Hofbauer Lorenz C , Houillier Pascal , Khan Aliya A , Levine Michael A , Mannstadt Michael , M Shoback Dolores , Vokes Tamara J , Zhang Pinggao , Marelli Claudio , Germak John , Gittoes Neil

PARADIGHM is an actively recruiting, prospective, observational registry (NCT01922440/EUPAS16927). The primary objective is to evaluate the safety and effectiveness of recombinant human parathyroid hormone, rhPTH(1-84), treatment in patients with chronic hypoparathyroidism under routine clinical care. The secondary objective is tocharacterize the clinical course of chronic hypoparathyroidism under conditions of routine clinical practice. At enrollment, registry inclusion crite...

ea0029p713 | Diabetes | ICEECE2012

Reducing Residual Vascular Risk Through combination Therapy with Fenofibrate and Alpha-Lipoic Acid in Patients with Ischemic Heart Disease and Type 2 Diabetes Mellitus

Zhuravlyova L. , Lopina N.

Purposes: To investigate effects of combination therapy with fenofibrate and α-lipoic acid (ALA) on atherogenic dyslipidemia, which determines the residual vascular risk and endothelial dysfunction, levels of proinflammatory mediators in patients with ischemic heart disease (IHD) and type 2 diabetes mellitus (T2DM).Methods: We examined 42 patients with IHD and T2DM (19 males, age 60.5±4.7 years). Baseline characteristics of patients included hi...

ea0006p17 | Cytokines | SFE2003

EFFECT OF CATHEPSIN D AND PROSTATE SPECIFIC ANTIGEN ON LATENT TRANSFORMING GROWTH FACTOR-BETA IN BREAST CANCER CELL LINES

Lai L , Wong S

Transforming growth factor-beta (TGF-beta)is present, predominantly in latent forms, in normal and malignant breast tissue. The mechanisms by which TGF-beta is activated physiologically remain largely an enigma. The aim of this study was to assess whether the proteases, cathepsin D and PSA could activate latent TGF-beta 1 and 2 in the MCF-7 hormone responsive and MDA-MB-231 hormone unresponsive human breast cancer cell lines. For the experiments, 1 x 106cells were s...

ea0029p617 | Diabetes | ICEECE2012

Experience of diabetic dyslipidemia correction in patients with ischemic heart disease and type 2 diabetes mellitus using α-lipoic acid in combination therapy

Lopina N. , Zhuravlyova L.

Purposes: To investigate the effects of α-lipoic acid (ALA) on diabetic dyslipidemia, endothelial dysfunction, levels of adiponectin and proinflammatory mediators in combination therapy of patients with ischemic heart disease (IHD) and type 2 diabetes mellitus (T2DM).Methods: We examined 40 patients with IHD and T2DM (19 males, age 60.5±4.7 years). Baseline characteristics of patients included history of IHD (7.2±2.3 years), T2DM (4.7&#177...

ea0029p1515 | Pituitary Clinical | ICEECE2012

Familial central diabetes insipidus with extremely high water intake

Pigarova E. , Rozhinskaya L. , Dzeranova L. , Zenkova T. , Tiulpakov A.

Water intake in central diabetes insipidus (CDI) usually falls in range of 3–20 l a day. Intake of more than 20 l is regarded as physiologically unnecessarily even in the absence of antidiuretic hormone. We describe a family with 8 members suffering from autosomal recessive form of CDI due to mutation C105Y (codon numeration is given for preprovasopressin) in AVP gene. In all family members disease had presented in neonatal period or early childhood. It is remarkable that...

ea0081p561 | Calcium and Bone | ECE2022

Nutritional and clinical manifestations of normocalcemic hyperparathyroidism in women: interim results from a case-control cross-sectional study evaluating dietary calcium intake with three validated questionnaires

Malagrino Matteo , Altieri Paola , Clarke Bart , Pagotto Uberto , Zavatta Guido

Context: Normocalcemic hyperparathyroidism (NHPT) is considered as an earlier or milder phenotype compared to traditional primary hyperparathyroidism (PHPT). To make a correct diagnosis, secondary hyperparathyroidism due to low calcium intake must be excluded. Whether calcium intake might affect presentation of PHPT vs NHPT has never been addressed consistently.Objective: To describe patients with a diagnosis of NHPT or PHPT in relation to their calcium ...

ea0026p300 | Pituitary | ECE2011

Secondary erythrocytosis due to acromegaly

Pigarova E , Dobracheva E , Dzeranova L , Rozhinskaya L

A 53-year-old man with acromegaly was referred for neurosurgical treatment. At admission: GH 240 ME/l at all time points of glucose tolerance test, IGF1 – 415.1 ng/ml, brain MRI showed pituitary adenoma 34×32×27 mm extending suprasellar, deforming and displacing optic chiasm, parasellar to both cavernous sinuses and surrounding left internal carotid artery. Clinical blood tests revealed marked erythrocytosis – 6.1×1012, Hb – 200 g/l, HC...

ea0029p214 | Calcium &amp; Vitamin D metabolism | ICEECE2012

Lack of effects of high dose colecalciferol (D3) on insulin sensitivity and metabolic markers in type 2 diabetic patients: a double-blind, randomised, placebo-controlled trial

Kampmann U. , Mosekilde L. , Schmitz O. , Moller N. , Christensen B. , Wamberg L. , Orskov L.

Introduction: Vitamin D insufficiency is common in subjects with type 2 diabetes. Observational studies suggest that vitamin D plays a role in the pathogenesis of type 2 diabetes. However, results of intervention studies have been inconsistent. We investigated the effects of improving vitamin D status on insulin sensitivity and inflammatory markers in type 2 diabetic patients with vitamin D insufficiency.Methods: A double blind, randomized, placebo contr...